| Date | Title | Description |
| 08.04.2026 | Sidewinder Therapeutics: $137 Million Raised For Bispecific ADC Cancer Therapies | Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific antibody-drug conjugates, announced the closing of an oversubscribed $137 million Series B financing round to advance its oncology pipeline into clin... |
| 08.01.2026 | Mediar Therapeutics Secures $76M to Advance Fibrosis Therapies | Mediar Therapeutics secured a substantial $76 million in Series B financing. This Boston-based biotechnology firm is advancing novel, first-in-class therapies to combat fibrosis. The funding fuels its clinical pipeline. Key programs include... |
| 07.01.2026 | Mediar Therapeutics: $76 Million Series B Raised As Fibrosis Programs Advance | Mediar Therapeutics, a clinical-stage biotech developing first-in-class therapies designed to halt fibrosis, said it closed an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG as it advances a portfolio of ... |
| 07.01.2026 | Mediar Therapeutics Raises $76M in Series B Financing | Mediar Therapeutics, Inc., a Boston, MA-based clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, raised $76m in Series B financing.
The round was co-led by Amplitude Ventures and ICG, with par... |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | AAVantgarde: $141 Million Series B Closed To Advance Clinical Programs For Stargardt Disease And Usher 1B Syndrome | AAVantgarde Bio has closed a $141 million (€122 million) Series B financing to advance its lead clinical programs targeting inherited retinal diseases. The financing round was co-led by Schroders Capital, Atlas Venture, and Forbion, with pa... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding.
The round was led by Schroders Capital, as well as existing investors ... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 01.10.2025 | Crystalys Therapeutics: $205 Million Series A Raised For Transforming Gout Treatment | Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can lead to painful arthritis flare-ups. The... |
| 30.09.2025 | Crystalys Therapeutics Raises in $205M Series A Funding | Crystalys Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company, raised $205M in Series A funding.
The round was led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors,... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding.
The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 15.02.2025 | Newleos Therapeutics: A New Dawn in Neuropsychiatric Treatment | In the world of mental health, the need for innovation is as urgent as a fire alarm. Newleos Therapeutics has stepped into this arena with a bold vision and a hefty $93.5 million in Series A funding. This clinical-stage neuroscience company... |
| 14.02.2025 | Newleos Therapeutics: $93.5 Million (Series A) Raised For Transforming Treatment Of Neuropsychiatric Disorders | Newleos Therapeutics—a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development—announced the closing of an oversubscribed $93.5 million Series A financing. Goldman Sachs Alternatives led ... |
| 13.02.2025 | Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines | -Newleos aims to develop first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions-
-Multiple clinical-stage programs licensed from Roche, ready for pr... |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding.
The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 09.11.2024 | Evommune Secures $115 Million to Tackle Chronic Inflammatory Diseases | In the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune... |
| 08.11.2024 | Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases | Evommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently
The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 19.03.2024 | Engrail Therapeutics raises $157M Series B | Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round.
Th... |
| 05.05.2023 | Longwood Fund Closes Sixth Fund, at $180M | General Partners Christoph Westphal and David Steinberg
Longwood Fund, a Boston, MA-based venture capital firm dedicated to creating and investing in science-based companies, closed its sixth fund, at $180M.
This fund will continue focusing... |
| 05.01.2023 | Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference | CAMBRIDGE, Mass. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Bedding... |
| 08.09.2022 | Photys Therapeutics raises $75M in Series A funds to control disease-causing proteins | A new drug company emerged from stealth on Thursday.
Photys Therapeutics debuted with a $75 million Series A funding round led by MPM Capital. The Boston-based company was founded last year by Longwood Fund — a venture capital firm that cre... |
| 25.10.2020 | Startup focused on B-cell therapies launched with $52M in Series A | “We have an ambitious plan to be the company that knows how to make B cells and mirror them precisely and make them at scale,” Aleks Radovic-Moreno, Be Biopharma’s president and director, said in a phone interview.
B cells, which play a lea... |
| 16.11.2018 | Lessons Learned: How to balance residency and a budding career in venture capital | Lessons Learned is STAT Plus’ column on careers in biomedicine. If you’re thinking of jumping from academics to industry/business or vice versa, join us for useful tips. And if you’ve recently jumped, send us a note: [email protected] Your ... |
| 05.01.2016 | Daily funding roundup - January 5, 2016 | PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M
Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me... |
| 22.07.2015 | Daily funding roundup - July 22, 2015 | Events.com has now raised a total of $17M; Darktrace landed $22.5M; Kinetic Social closed $17.5M
Events.com has raised a new round of funding. The size of the round was undisclosed, but it was led by Arctaris and with participation from La ... |
| 16.07.2012 | Investors back female fertility treatment that may ‘reenergize’ eggs using stem cells | Based on infertility research by Jonathan Tilly at Massachusetts General Hospital, OvaScience’s lead program isolates a certain egg-producing stem cell found in the ovary and extracts the cells’ mitochondria, their main source of energy. As... |
| 28.12.2010 | Longwood Founders Management Closes Maiden Fund at $85M | Longwood Founders Management, LLC, a healthcare venture capital firm, closed its first fund at $85m.
Investors in Longwood Founders Fund, L.P. include GlaxoSmithKline, Genzyme, and several institutional investors.
Managed by partners Rich A... |
| - | Investors back female fertility treatment that may ‘reenergize’ eggs using stem cells | A company’s new technique to improve female infertility treatment based on the controversial idea that women aren’t in fact born with a finite number of eggs is getting the attention of investors — to the tune of more than $38 million raise... |
| - | Startup focused on B-cell therapies launched with $52M in Series A | After tackling two major research challenges, the founders of Be Biopharma are ready to announce their official launch along with a $52 million funding round. They are intent upon using the body’s B cells to treat a range of diseases.
The S... |
